Results 301 to 310 of about 137,002 (346)
Some of the next articles are maybe not open access.
Obesity and Glucagon-Like Peptide-1 Receptor Agonists
JAMAThis Viewpoint discusses factors associated with the prevalence of obesity worldwide and whether the novel glucagon-like peptide-1 receptor agonists (GLP-1) can help unlock a health systems response to the obesity pandemic.
Francesca, Celletti +2 more
openaire +2 more sources
[Glucagon-like peptide-1 receptor agonists].
Nihon rinsho. Japanese journal of clinical medicine, 2015Recently, the number of diabetic patients with obesity has increased by changes in life-style including food and physical exercise. Appearance of incretin-related drugs has given us more options for treating type 2 diabetes, and they are evaluated in regard to realizing appropriately controlled glycemic status.
Yamato, Mashimo, Kazuhiro, Eto
openaire +1 more source
Cardioprotective Effects of Glucagon-Like Peptide 1 Receptor Agonists
Kardiologiia, 2014In this paper we discuss pathogenetic mechanisms of cardiovascular risk reduction in patients with type 2 diabetes mellitus by glucagon-like peptide 1 (GLP-1) receptor agonists. Results of experimental studies and randomized clinical studies are presented, and perspectives for using GLP-1 agonists in patients with diabetic cardiovascular complications ...
A S, Ametov +2 more
openaire +2 more sources
Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry
Journal of Clinical PsychopharmacologyThe glucagon-like peptide 1 (GLP-1)–based diabetes and obesity drug semaglutide, with trade names Ozempic and Wegovy, will become the second best-selling drug in 2024, with estimated worldwide Ozempic sales of US ~$16 billion. Finally, the pharmacological treatment of obesity seems to have a breakthrough after decades of setbacks, with previous weight ...
Himmerich, Hubertus, McElroy, Susan L
openaire +3 more sources
Glucagon-like peptide-1 receptor action in the vasculature
Peptides, 2019Glucagon-like peptide-1 receptor (GLP-1R) agonists augment insulin secretion and are thus used clinically to improve glycemia in subjects with type 2 diabetes (T2D). As recent data reveal marked improvements in cardiovascular outcomes in T2D subjects treated with the GLP-1R agonists liraglutide and semaglutide in the LEADER and SUSTAIN-6 clinical ...
Malak Almutairi +2 more
openaire +2 more sources
Glucagon-like peptide-1 receptor agonists
2016Native glucagon-like peptide-1 (GLP-1) is not practical for therapeutic use due to a short half-life caused by ubiquitous, fast, and effective in vivo degradation by the enzyme dipeptidyl peptidase-4 (DPP-4).
openaire +1 more source
Glucagon-like peptide-1 receptor agonists and the eye
Current Opinion in OphthalmologyPurpose of review Glucagon-like peptide-1 receptor agonists (GLP-1RA) have gained popularity as an antidiabetic and weight loss agent with protective cardiovascular outcomes, but attention to the potential ocular side effects has grown.
David L, Zhang, Avni P, Finn
openaire +2 more sources
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Nature Reviews Cardiology, 2023J. Ussher, D. Drucker
semanticscholar +1 more source
[The glucagon-like peptide-1 receptor-agonist semaglutide].
Ugeskrift for laeger, 2020Semaglutide is a glucagon-like peptide-1 receptor-agonist (GLP-1 RA), which is injected subcutaneously once a week for treatment of Type 2 diabetes. In this review, the present results of semaglutide treatment are presented. Semaglutide has been evaluated in more than 8,000 patients across the spectrum of Type 2 diabetes.
Amalie Dyhrberg, Boje +3 more
openaire +1 more source